Biotronik Wins FDA Clearance of MultiPole Pacing Device

Biotronik has gained FDA marketing clearance of its MultiPole Pacing (MPP) technology, for treatment of heart failure patients who have been non-responsive to cardiac resynchronization therapy (CRT).

The device systems include MPP and feature ProMRI technology, providing patients with access to critical diagnostic imaging scans as needed.

These devices are also equipped with a dedicated MRI sensor that converts the device to MRI mode and then automatically returns to its permanent program when the scan is complete.

MPP technology is available on BIOTRONIK's newest line of CRM devices, including the Ilivia series for tachycardia. — Cynthia Jessup